omega-n-methylarginine has been researched along with Chronic Kidney Diseases in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bode-Böger, SM; Emrich, IE; Fliser, D; Heine, GH; Martens-Lobenhoffer, J; Wagenpfeil, S; Zawada, AM | 1 |
| Chen, Y; Liu, X; Shang, R; Xu, X | 1 |
| Bech, JN; Hansen, AB; Jensen, JM; Larsen, T; Mose, FH; Pedersen, EB | 2 |
| Clish, CB; Coresh, J; Fox, CS; Gerszten, RE; Hwang, SJ; Larson, MG; Levy, D; Li, M; McMahon, GM; O'Donnell, CJ; Rhee, EP; Tin, A; Yang, Q; Young, JH | 1 |
1 review(s) available for omega-n-methylarginine and Chronic Kidney Diseases
| Article | Year |
|---|---|
Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease.
Topics: Amidohydrolases; Animals; Arginine; Endothelium, Vascular; Heart Failure; Humans; Nitric Oxide Synthase; omega-N-Methylarginine; Renal Insufficiency, Chronic; Risk Factors; Signal Transduction | 2018 |
2 trial(s) available for omega-n-methylarginine and Chronic Kidney Diseases
| Article | Year |
|---|---|
Effect of atorvastatin on renal NO availability and tubular function in patients with stage II-III chronic kidney disease and type 2 diabetes.
Topics: Aged; Arginine Vasopressin; Atorvastatin; Atrial Natriuretic Factor; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubules; Male; Middle Aged; Natriuretic Peptide, Brain; Nitric Oxide; omega-N-Methylarginine; Pulse Wave Analysis; Pyrroles; Renal Insufficiency, Chronic; Treatment Outcome; Vascular Stiffness; Vasopressins | 2014 |
Effects of atorvastatin on systemic and renal NO dependency in patients with non-diabetic stage II-III chronic kidney disease.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Blood Pressure; Cross-Over Studies; Double-Blind Method; Epithelial Sodium Channels; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Middle Aged; Nitric Oxide; omega-N-Methylarginine; Pyrroles; Renal Insufficiency, Chronic; Vascular Stiffness | 2014 |
2 other study(ies) available for omega-n-methylarginine and Chronic Kidney Diseases
| Article | Year |
|---|---|
Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease.
Topics: Aged; Arginine; Biomarkers; Cardiovascular Diseases; Chromatography, Liquid; Disease Progression; Female; Germany; Humans; Incidence; Male; Middle Aged; omega-N-Methylarginine; Prognosis; Renal Dialysis; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors | 2018 |
Urinary metabolites along with common and rare genetic variations are associated with incident chronic kidney disease.
Topics: Aged; Amino Acid Transport Systems, Basic; Amino Acids; Biomarkers; Case-Control Studies; Chi-Square Distribution; Female; Genetic Predisposition to Disease; Glycine; Histidine; Humans; Incidence; Logistic Models; Lysine; Male; Mass Spectrometry; Massachusetts; Metabolomics; Middle Aged; Odds Ratio; Oligonucleotide Array Sequence Analysis; omega-N-Methylarginine; Phenotype; Polymorphism, Single Nucleotide; Proportional Hazards Models; Prospective Studies; Protective Factors; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Urinalysis | 2017 |